- Abbott’s first-quarter adjusted earnings per share (EPS) came in at $1.09, surpassing analyst expectations of $1.07 and showing growth from the previous year’s $0.98.
- Total net sales for the quarter were $10.36 billion, marking a 4% increase year-over-year, but slightly below the estimated $10.4 billion.
- Nutrition sales reached $2.15 billion, which is a 3.8% increase compared to last year and higher than the estimated $2.11 billion.
- Diagnostics sales fell by 7.2% year-over-year to $2.05 billion, missing the forecast of $2.19 billion.
- Sales from established pharmaceuticals increased by 2.8% to $1.26 billion, slightly above the predicted $1.24 billion.
- Medical devices sales performed strongly, rising by 9.9% to $4.90 billion, outpacing expectations of $4.85 billion.
- Diabetes care sales experienced significant growth of 16%, reaching $1.83 billion, and beating the estimate of $1.81 billion.
- Abbott has reaffirmed its full-year 2025 financial guidance.
- The stock currently has 20 buy ratings, 9 hold ratings, and no sell ratings.
Abbott Laboratories on Smartkarma
Analyst coverage of Abbott Laboratories on Smartkarma by Baptista Research provides valuable insights into the company’s performance and growth trajectory. In a report titled “Abbott Laboratories: An Insight Into Its Medtech & Diagnostic Growth Trajectory & Why It May Not Be Enough To Warrant A ‘Buy’ Rating!” the analysts highlight the company’s strong financial performance in the fourth quarter of 2024, with a solid sales growth of 10% excluding COVID-19 testing. This growth was driven by progress in business segments like Adult Nutrition and Medical Devices, particularly in continuous glucose monitoring systems.
Furthermore, in another report titled “Abbott Laboratories: A Tale Of Pipeline Productivity and Innovation! – Major Drivers,” Baptista Research underscores Abbott’s robust performance in the third quarter of 2024, showcasing over 8% organic sales growth and adjusted earnings per share of $1.21. Despite varying sector performances, Abbott’s effective execution of its strategy is evident, with notable growth in the U.S. Pediatric Nutrition segment at 12%. These reports provide valuable analysis for investors evaluating Abbott Laboratories‘ potential in the market.
A look at Abbott Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbott Laboratories, a global healthcare company with a focus on a diverse range of health products, has been given positive ratings across the board by Smartkarma’s Smart Scores. The company has scored a 4 for Growth, indicating strong potential for expansion and development in the future. This suggests that Abbott Laboratories is well-positioned to capitalize on market opportunities and drive long-term growth.
Additionally, Abbott Laboratories has received high scores in Resilience and Momentum, with ratings of 4 and 5 respectively. This suggests that the company has shown stability in the face of challenges and has strong positive momentum in the market. Overall, with solid ratings in key areas such as Growth, Resilience, and Momentum, the long-term outlook for Abbott Laboratories appears promising based on the Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
